Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease

Interstitial Lung Disease Clinical Trial

— CATR-PAT  

Official title:

Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03770663
• Other study ID #: P140217
• Secondary ID: 2016-002921-12
• Status: Recruiting
• Phase: Phase 3
• Start date: February 5, 2021
• Est. completion date: January 2, 2024

Study information

• Verified date: February 2021
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Olivier BENVENISTE, MD
• Phone: +33 (0)1 42 16 10 88
• Email: olivier.benveniste[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

"Antisynthetase syndrome (ASS) is one of the most severe inflammatory myopathy (IM), due to pulmonary involvement (interstitial lung disease, ILD). Until now, the most commonly used immunosuppresive therapy in Europe is Cyclophosphamide followed by different immunosuppressive drugs as maintenance therapy, including Azathioprine (and so called " European Strategy "). In the USA however, the first-line immunosuppressive treatment is Tacrolimus (so called " American Strategy "). None of these two different strategies has ever been studied prospectively, and there is no clear comparison of short and long-term treatment efficacy and tolerance. Thus, there are yet no evidences helping the clinicians in the therapeutic management of patients with ASS-related ILD.

The aim of this study is therefore to compare both strategies as first line treatments or in relapsing patients : CATR.PAT study is a 52 weeks, randomized, comparative, controlled, open-labeled, phase III, therapeutic clinical trial, comparing two treatment strategies."

Description:

"During the study period, according to randomization into two groups (n=38 patients, respectively), patients will receive either:

• Group 1 & 2 : 3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12

In association with :

• Group 1 : European Standard of care :

6 IV pulses of Cyclophosphamide (1000 mg) followed from M5 to M12 by oral Azathioprine (2 mg/kg/day), with a maximum of 150 mg/d)

• Group 2 : American Strategy Tacrolimus is given orally from M0 to M12 (started at the initial dose of 2x2mg/d). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15 ng/ml."

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: January 2, 2024
• Est. primary completion date: January 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18

2. Signed informed consent

3. Affiliation to the Social security system

4. Diagnosis of ASS: positive test for any of the 5 anti-tRNA synthetase antibodies routinely tested (ELISA, Luminex or Linear-dot), including anti-Jo-1, anti-PL7, anti-PL12, anti-EJ and anti-OJ.

5. Diagnosis of ILD-related ASS: interstitial lung disease on HRCT.

6. Moderate to severe ILD on PFT : FVC < 80% and or cDLCO < 70%

7. beta-HCG test negative or negative uterine echography (for women of child bearing potential)

8. Women of childbearing potential must have an oral contraception (macroprogestatifs) during all the duration of study treatment and 12 months after the last dose of study treatment

9. Males who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of study treatment and 6 months after the last dose of study treatment

Exclusion Criteria:

1. Pregnancy and/or breast feeding

2. Others contraindications to the treatments, including hypersensitivity to the drug (including excipient and active compounds), medical contraception contraindications, severe renal failure, severe hepatic insufficiency and severe psychiatric disorders. Specific contraindications are listed for each experimental medication in Table 6 (according to updated Summary of product characteristics, see Appendix 8)

3. Fever or active bacterial infection (ie. septicemia, pneumopathy, pyelonephritis, acute prostatitis …), or parasitic infection (ie. Anguillulosis …),or fungal infection (ie. Invasive pulmonary aspergillosis …), or viral infection (HIV seropositivity, Active Tuberculosis, active B/C viral hepatitis, CMV, active EBV…)

4. Active neoplasm

5. Previous inefficacy of Cyclophosphamide, Azathioprine or Tacrolimus, not related to adhesion problems.

6. Previous use of 3 daily IV steroids < 3 months before patient's enrollment.

7. ASS-related ILD worsening or relapse under Prednisone > 0.5 mg/kg/day

8. Previous use of Cyclophosphamide, Azathioprine or Tacrolimus in the last 6 months.

9. Severe ASS requiring ICU (respiratory disease, myocarditis), plasma exchange or IV-Ig.

10. Positivity of auto-antibodies associated to Systemic Sclerosis (anti-Telomerase, anti-Centromères, anti-Polymerase III).

11. Patients with QTc > 450 msec

12. Patients with history of long QT syndrome (including familial) or ventricular arrhythmias

13. Concomitant use of drugs prolonging QT / QTc (list of treatments in annex)

14. Hypokalemia

15. Patients with pulmonary hypertension detected on echocardiography during the screening/selection visit (systolic pulmonary artery pressure (PAP) was 37-50 mmHg, and/or tricuspid regurgitation velocity 2.8-3.4 ms-1) are excluded.

Related Conditions & MeSH terms

• Antisynthetase Syndrome (ASS)
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Myositis
• Syndrome

Intervention

Drug:
• Cyclophosphamide and azathioprine
European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
• Tacrolimus
American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.

Locations

Country	Name	City	State
France	Hôpital Universitaire Pitié Salpêtrière	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	Compare the efficacy of Cyclophosphamide and Azathioprine vs Tacrolimus in patients with ASS related-ILD Time from the initiation of treatment to the first event related to ASS related-ILD (progression free survival)	From baseline to 12 months
Secondary	Variation of the six minute walk tests	Compare Global variation of the M0 and M12-six minute walk tests (distance in meter, differential of saturation in %)	at baseline, 3 months, 6 months, 9 months and 12 months
Secondary	Forced Vital Capacity (FVC)	Compare Global variation of M0 and M12-FVC (both absolute and %)	at baseline, 3 months, 6 months, 9 months and 12 months
Secondary	Diffusing Lung Carbon Monoxyde Capacity (cDLCO)	Compare Global variation of M0 and M12 cDLCO (both absolute and %)	at baseline, 3 months, 6 months, 9 months and 12 months
Secondary	Rate of pulmonary improvement	Lung improvement is defined (in the absence of any other pulmonary disease) by 3A. Improvement of at least 20% of the dyspnea visual scale score (1-10) 3B. and/or improvement of pulmonary function tests: increase of the baseline FVC by 10% (% patient predicted value or absolute value) or of the baseline cDLCO by 15% (% patient predicted value or absolute).; 3C. and/or improvement of ILD on HRCT-scan (-5% involvement of the lung parenchyma evaluated by the extension score and -10% of the coarseness score of fibrosis): see Appendix 3' 3D. and/or improvement of PaO2 > 10 mmHg (FiO2=21%), without hyperventilation at any test	at baseline, 3 months, 6 months, 9 months and 12 months
Secondary	Time to extra-pulmonary improvement	Evaluated as follow : 4A. improvement of the muscle involvement assessed by muscle manual testing (MMT/150, see Appendix 5) at each visit, is defined by an increased score > 20% 4B. biological improvement of the muscle involvement, assessed by creatine kinase levels performed at every visit, is defined by a decreased of baseline creatin kinase > 50% (IU/ml) 4C. improvement of the joint involvement, assessed by the ACR score at every visit is defined by a decrease > 20% of baseline number of swelling and painful joints.	at each visits
Secondary	Rate of extra-pulmonary improvement	Extra-pulmonary improvement (muscle and joint involvements) is evaluated as follows : 5A. improvement of the muscle involvement, assessed by MMT/150 muscle testing at baseline and M12, is defined by an increased score > 20% 5B. improvement of the joint involvement, assessed by the ACR score at each visit is define by a decrease > 20% of baseline number of swelling and painful joints.	at baseline and 12 months
Secondary	Treatments tolerance	6A. any serious adverse event attributable to any experimental medication, which requires hospitalization, is recorded at any time 6B. side effects are declared by the patients, recorded and reported by the investigators at every visit 6C. the number of patients switching of experimental treatment is recorded 6D. the cumulative dose (mg/kg) of steroids will be compared at the end of the study	At every visit
Secondary	Treatment Efficacy	6A. any serious adverse event attributable to any experimental medication, which requires hospitalization, is recorded at any time 6B. side effects are declared by the patients, recorded and reported by the investigators at every visit 6C. the number of patients switching of experimental treatment is recorded 6D. the cumulative dose (mg/kg) of steroids will be compared at the end of the study	at every visit
Secondary	Quality of Life with SF-36 scale		Baseline, 6 months, 12 months